Stay updated with breaking news from Plasma resources. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In the 19th century, women would sell their hair for a little pocket money. For a time, hair shaved from prison inmates helped meet surging demand for wigs and… ....
Variants of concern risk at plasma donation site in Saskatoon newsoptimist.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsoptimist.ca Daily Mail and Mail on Sunday newspapers.
Article content A Saskatoon blood bank has closed its doors until further notice in response to an increased risk from COVID-19 variants of concern over six days this month. The Saskatchewan Health Authority issued an alert on Friday that anyone who visited the Canadian Plasma Resources facility during business hours on April 8 and 10 and April 13 to 16 must quarantine for 14 days from the date of potential exposure. We apologize, but this video has failed to load. Try refreshing your browser. Canadian Plasma Resources in Saskatoon closes due to COVID-19 risk Back to video A post on the Canadian Plasma Resources website dated Friday says the location at 300 – 1222 Quebec Ave. will be closed for the rest of the week or until the medical health officer deems it safe to reopen. ....
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras News provided by Share this article Share this article LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ( Liminal BioSciences or the Company ), a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Company s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers. The new clinical trial is designed to look at more frequent daily dosing (twice and three times daily) of fezagepras up to 2,400mg for a total of 14 days. The clinical trial is a standard placebo-controlled Phase 1 ascending dose design in healthy volunteers. The clinical trial endpoints will include safety, pharmacokinetics, and exploratory biomarkers related to the mechanism of action of fezagepras. The data from this clinical trial will be used to guide se ....